Back to Results
First PageMeta Content
Biomarker / Medicine / Astex / Acute myeloid leukemia


September 30, 2013 Astex Pharmaceuticals Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress DUBLIN, Calif., Sept. 30, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a ph
Add to Reading List

Open Document

File Size: 16,64 KB

Share Result on Facebook

City

New Orleans / Amsterdam / /

Company

Autumn Acquisition Corporation / Astex Pharmaceuticals Inc. / Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals Astex Pharmaceuticals / /

Continent

Asia / Europe / /

Country

United States / Netherlands / /

Currency

USD / /

Event

M&A / FDA Phase / General or Shareholder Meeting / /

Facility

Temple University / Fels Institute / /

IndustryTerm

prominent pharmaceutical / treatment of relapsed/refractory acute myeloid leukemia / pharmaceutical / /

MedicalCondition

cancer / Hematological Malignancies / silenced tumor / acute myeloid leukemia / /

MedicalTreatment

bone marrow transplants / /

Organization

Congress / American Society of Hematology Annual / Fels Institute for Cancer and Molecular Biology / Temple University / Philadelphia / U.S. Securities and Exchange Commission / European Cancer Congress DUBLIN / /

Person

Jean-Pierre Issa / /

Position

financial advisor / Governor / Professor / financial and legal advisors / Director / executive officers / /

Product

DACOGEN / SGI-110 / presentation / LINE-1 / SGI-110-01 / /

ProvinceOrState

Pennsylvania / Louisiana / California / /

PublishedMedium

Molecular Biology / /

Technology

gene expression / /

URL

www.sec.gov / http /

SocialTag